Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Institution
- Publication
- Publication Type
- File Type
Articles 1 - 4 of 4
Full-Text Articles in Oncology
Oncolog, Volume 47, Number 12, December 2002, Dawn Chalaire, Karen Stuyck, Raymond Sawaya Md
Oncolog, Volume 47, Number 12, December 2002, Dawn Chalaire, Karen Stuyck, Raymond Sawaya Md
OncoLog MD Anderson's Report to Physicians (All issues)
- Advances in Imaging Lead to More Targeted Radiation Treatments
- Imaging Techniques Follow the Movements of Tumors During and Between Radiation Treatments
- Evolution of Conformal Radiation Therapy Continues: IMRT Called 'the Next Level of Conformality'
- DiaLog: The Caregiver: An Unsung Hero, by Raymond Sawaya, MD, Professor and Chair, Department of Neurosurgery
- Support Groups, Classes Teach Caregivers How to Care for Patients and Themselves
Subsets More Likely To Benefit From Surgery Or Prophylactic Cranial Irradiation After Chemoradiation For Localized Non-Small-Cell Lung Cancer, Bruce Keith, Mark Vincent, Larry Stitt, Anna Tomiak, Richard Malthaner, Edward Yu, Pauline Truong, Richard Inculet, Michael Lefcoe, A. Dar, Walter Kocha, Ian Craig
Subsets More Likely To Benefit From Surgery Or Prophylactic Cranial Irradiation After Chemoradiation For Localized Non-Small-Cell Lung Cancer, Bruce Keith, Mark Vincent, Larry Stitt, Anna Tomiak, Richard Malthaner, Edward Yu, Pauline Truong, Richard Inculet, Michael Lefcoe, A. Dar, Walter Kocha, Ian Craig
Edward Yu
After chemoradiation for localized non-small-cell lung cancer, surgery and prophylactic cranial irradiation (PCI) have been used as additional therapies. Less than a third of patients develop brain recurrences, or have local recurrence as their sole initial site of recurrence; these are groups that would benefit from PCI or surgery, respectively. Pretreatment identification of patients more likely to benefit from surgery or PCI would be useful. A retrospective analysis of 80 patients was performed to determine prognostic factors for such patterns of failure. Twenty-nine patients were subsequently selected for surgery in a nonrandomized manner. Seventeen patients had isolated local initial recurrence …
Electric Field Enhanced Plasmid Delivery To Liver Hepatocellular Carcinomas, Richard Gilbert, Mark J. Jaroszeski, Loree Heller, Richard Heller
Electric Field Enhanced Plasmid Delivery To Liver Hepatocellular Carcinomas, Richard Gilbert, Mark J. Jaroszeski, Loree Heller, Richard Heller
Bioelectrics Publications
Electric field enhanced molecular delivery for cancer research and treatment is a new technology that has demonstrated its effectiveness in clinical trials using bleomycin or cisplatin (Heller, R., Gilbert, R., Jaroszeski, M. J. Clinical applications of electrochemotherapy, Advanced Drug Delivery Reviews 35,119-129, 1999), as chemotherapeutic agents. The technology is being investigated in research applications for applicability as a method to enhance gene expression in a target tumor. Success is predicated on an appropriate effective electric field mediated delivery protocol that triggers significant appropriate gene expression duration and levels. An electric field mediated delivery protocol includes a set of conditions …
Prophylactic Cranial Irradiation Revisited: Cost-Effectiveness And Quality Of Life In Small-Cell Lung Cancer, T. Tai, Edward Yu, Peter Dickof, Glen Beck, Jon Tonita, Tete Ago, David Skarsgard, Marlene Schmidt, Matthew Schmid, John Liem
Prophylactic Cranial Irradiation Revisited: Cost-Effectiveness And Quality Of Life In Small-Cell Lung Cancer, T. Tai, Edward Yu, Peter Dickof, Glen Beck, Jon Tonita, Tete Ago, David Skarsgard, Marlene Schmidt, Matthew Schmid, John Liem
Edward Yu
PURPOSE: To investigate the therapeutic usefulness and cost-effectiveness of prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer (SCLC) who had achieved a complete remission. METHODS: A retrospective chart review was undertaken of all patients diagnosed in Saskatchewan with SCLC between 1987 and 1998 inclusive. Patients who achieved a complete remission were divided into two groups, depending on whether they underwent PCI (PCI+ and PCI-, respectively). The quality-of-life-adjusted survival was estimated by the Q-TWiST method (quality time without symptoms and toxicity). The mean incremental costs per month of incremental OS were calculated in a cost-effectiveness analysis. RESULTS: Among …